文章摘要
张丹丹,李会英,毛玉山,吴伦,黄静.西格列汀与格列齐特缓释片联用甘精胰岛素治疗2型糖尿病的疗效与安全性评价[J].中国临床保健杂志,2017,20(1):67-70.
西格列汀与格列齐特缓释片联用甘精胰岛素治疗2型糖尿病的疗效与安全性评价
Comparison of the efficacy and safety of the sitagliptin plus glargine insulin or the gliclazide plus glargine insulin in patients with type 2 diabetes
投稿时间:2016-09-19  
DOI:10.3969/J.issn.1672-6790.2017.01.021
中文关键词: 糖尿病,2型  格列齐特  二肽基肽酶Ⅳ抑制剂
英文关键词: Diabetes mellitus,type 2  Gliclazide  Dipeptidyl-peptidase IV inhibitors〖FL
基金项目:宁波大学校级科研项目(XYY16048)
作者单位E-mail
张丹丹 宁波大学医学院附属医院,宁波 315020 dannizdd@163.com 
李会英 宁波大学医学院附属医院,宁波 315020  
毛玉山 宁波大学医学院附属医院,宁波 315020  
吴伦 宁波大学医学院附属医院,宁波 315020  
黄静 宁波大学医学院附属医院,宁波 315020  
摘要点击次数: 3377
全文下载次数: 1653
中文摘要:
      目的 对西格列汀与格列齐特缓释片联合甘精胰岛素治疗2型糖尿病(T2DM)的疗效和安全性进行比较。方法 以83例T2DM患者为研究对象,按照随机数字表法分为观察组与对照组。观察组使用西格列汀联合甘精胰岛素的用药方案,对照组使用格列齐特缓释片联合甘精胰岛素的用药方案。均治疗16周,监测治疗前后空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、空腹胰岛素水平(FIns)、胰岛素抵抗指数(HOMA-IR)、体质量指数(BMI)等指标以及胰岛素用量、不良反应的发生情况。结果 治疗后两组的血糖控制均改善,FPG、2hPG、HbA1c、HOMA-IR水平较治疗前均明显下降,FIns均明显升高(P<0.05)。治疗后水平比较,对照组FPG降低较观察组明显(P<0.05),但是观察组2hPG降低更明显(P<0.05);HbA1c达标率、HOMA-IR两组间前后差值比较,差异无统计学意义(P>0.05)。观察组的BMI水平较对照组下降了6.25%,胰岛素用量减少了12.92%,差异有统计学意义(P<0.05)。安全性方面,观察组低血糖的发生率(2.38%),与对照组(9.76%)比较,差异有统计学意义(P<0.05)。结论 西格列汀联用甘精胰岛素治疗2型糖尿病使血糖控制良好,安全性高。
英文摘要:
      Objective To investigate the efficacy and safety of the sitagliptin plus glargine insulin or the gliclazide plus glargine insulin in patients with type 2 diabetes.Methods Eighty-three patients with type 2 diabetes were randomly assigned to 2 group.The observation group was treated with sitagliptin plus glargine insulin,and control group was treated with gliclazide plus glargine insulin.The duration of treatment was 16 weeks.FPG,2hPG,HbA1c,FIns,HOMA-IR,BMI,insulin dosage and adverse events were recorded.Results Glycemic control was improved in both groups.FPG,2hPG,HbA1c,HOMA-IR were significantly decreased compared to pretreatment,FIns were significantly increased(P<0.05),FPG in control group were lower than those in observation group(P<0.05),but 2hPG in observation group were lower than those in control group(P<0.05);HbA1c targeting rate,HOMA-IR between the two groups had no significant difference.But the BMI level in observation group down by 6.25% compared with control group,also the insulin dose was reduced by 12.92%,the difference was statistically significant.There was significant difference between observation group(2.38%)and control group(9.76%) in the proportion of hypoglycemia too.Conclusion Sitagliptin combined with glargine had better effect safety in the treatment of type 2 diabetes.
查看全文     
关闭
分享按钮